Concerns that US tariffs on Australian pharmaceuticals could deliver a major blow to the economy appear overstated, according to the International Monetary Fund’s latest assessment of Australia’s outlook, which instead points to rising and mostly unavoidable health spending as the far more significant long-term policy challenge.
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 - - Australian Biotech -
Medibank funding expansion signals momentum for Emyria’s mental health model
February 16, 2026 - - Latest News -
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 - - Latest News -
Chimeric Therapeutics names experienced biotech leader as chair in board and executive refresh
February 16, 2026 - - Australian Biotech -
'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'
February 16, 2026 - - Latest News -
Rare Cancers Australia sets sights on 2026 Kosi Challenge with renewed fundraising momentum
February 15, 2026 - - Latest News -
PBS spending is driven less by explicit fiscal choices and more by the flow of recommendations
February 15, 2026 - - Latest News

